Introduction
============

Pradofloxacin (PRA), a new fluoroquinolone (FQ) drug, is used to treat bacterial infections in cats and dogs [@B12];[@B13]. It shares the core structure of common cyclopropyl-type FQs [@B6] but carries a cyano group at position C-8 and a bi-cyclic amine at C-7, S,S-pyrrolidinopiperidine (\[1S,6S\]-2,8-diazabicyclo\[4.3.0\]non-8-yl); the latter is also contained in moxifloxacin [@B16]. Concerning *in vitro*antibacterial activity, particularly low mutant prevention concentrations of PRA suggest a high potential for preventing the emergence of resistance under therapy [@B22]. Both substituents in combination are essential for its improved efficacy [@B25]. Furthermore, the CN group facilitates hydrolytic elimination of the amine moiety (i.e., drug inactivation) under the slightly alkaline conditions present in decaying animal waste [@B24]. Hence, PRA should be more readily biodegradable and thus ecologically favorable than conventional FQs.

Fungal degradation of FQs such as ciprofloxacin [@B21], enrofloxacin [@B10] and moxifloxacin [@B16] under defined *in vitro*conditions has been described in detail. However, all findings yet reported concerned decomposition of the amine substituent located at C-7 and the pyridone part of the FQ core. Eighty-seven metabolites of enrofloxacin produced by *Gloeophyllum striatum*DSM 9592, a basidiomycetous fungus causing brown rot decay of wood by employing a Fenton-type reaction mechanism [@B8];[@B18], could be resolved: The chemical structures of 18 metabolites were fully elucidated, while 69 metabolites needed to be postulated based on their molecular formula, retention time and the most likely chemical context [@B10]. Forty-eight additional metabolites were generated by seven taxonomically diverse *Basidiomycetes*indigenous to agricultural sites, including *Agrocybe praecox*DSM 13167 from soil [@B23]. Two postulated *cis,cis*-muconic acid-type congeners of enrofloxacin, metabolites 78 and 79 in [@B10], came closest to implying aromatic ring cleavage to have occurred. However, although chemically more stable, the latter metabolites may, alternatively, be formulated as tetra-hydroxylated constitutional isomers. Hence, stringent evidence proving biodegradation of the aromatic core part of a FQ has not yet been reported. Our aim was to characterize the basic degradation scheme for PRA in *G. striatum*and to attempt the identification of new types of metabolites, to be expected due to the presence of the cyano group at position C-8.

Materials and methods
=====================

Isolation and identification of metabolites
-------------------------------------------

Mycelia of *G. striatum*DSM 9592 were grown in a fourfold diluted malt broth, washed and then re-suspended in a defined mineral medium to give a concentration of about 2 mg dry weight per mL, as has been described previously [@B20]. The culture vessels, screw-capped 250-mL Duran^®^glass bottles, contained 30 mL of mycelial suspension but were otherwise identical with those described before. PRA was added at 27 ± 0.5 μg/mL, labeled with either 1.4 or 1.9 MBq of \[2-^14^C\]PRA or \[pyrrolidinopiperidine-7-^14^C\]PRA, respectively [@B24]. Both compounds had a radiochemical purity of \> 98%. Cultures were then incubated at room temperature in the dark. ^14^CO~2~produced was quantified as described before [@B20].

Emerging metabolites were monitored by high-performance liquid chromatography (HPLC), as described elsewhere [@B20]. The former eluent system was slightly modified in that the aqueous component A contained 10 mM ammonium formate, 1% formic acid and 1% isopropanol; once again, acetonitrile served as component B. By adding B, component A was linearly decreased to 94% between 2 and 5 min, then to 85% over 9 min, to 70% over 15 min, to 50% over 5 min, and to 0% over 10 min. A shallower gradient (B) needed to be applied during co-chromatographic identification of the metabolites as well as micro-preparative purification of single metabolites from collected peak fractions. The HPLC gradient was modified as follows: By adding compound B, component A was linearly decreased to 94% over 5 min, to 88% over 10 min, to 82% over 15 min, to 75% over 15 min, and to 50% over 5 min. In order to identify metabolite F-10, \[pyrrolidinopiperidine-7-^14^C\]PRA needed to be provided as substrate. In case of F-10, component B consisted of 10% of acetonitrile in methanol (vol/vol). The flow rate was 1 mL/min, throughout.

Mycelia were separated by centrifugation and the resulting pellets washed with 50 mL of sterile water. The combined supernatants were passed through a 0.45 μm pore-size filter, then freeze-dried and re-suspended in 2 mL of distilled water. Metabolites could be isolated from such stock solutions by micro-preparative HPLC and manual collection of the relevant gradient fractions. After checking purity by HPLC analysis, metabolites were concentrated again by freeze-drying and re-suspended appropriately for structure determination.

Structure determination
-----------------------

HPLC-mass spectrometry (HPLC-MS) was performed as described previously [@B20]. To characterize F-10, an isocratic mobile phase was used consisting of equal volumes of 25 mM ammonium acetate in water and methanol. Proton nuclear magnetic resonance (^1^H-NMR) spectra were recorded at 500 MHz in D~2~O containing 5% (vol/vol) of trifluoroacetic acid-d~1~, with acetone serving as an internal standard set at δ = 2.16 ppm [@B20]. High-resolution mass spectrometry (HR-MS) and determination of the molecular formula have been described by [@B10]. Fourier transformed infrared spectroscopy (FT-IR) specifically indicated the presence of the conjugated nitrile group in PRA by absorbance at 2205 cm^-1^. Of metabolite F-13, a sample of about 10 μg was imbedded in a micro potassium bromide disc. This was analyzed by using a UMA 500 microscope mounted to a FTS 60A spectrometer (Bio-Rad, Krefeld, Germany).

Results
=======

Metabolites of PRA formed by *G. striatum*
------------------------------------------

After 8 weeks, ^14^CO~2~production from \[2-^14^C\]PRA and \[pyrrolidinopiperidine-7-^14^C\]PRA, applied at 10 μg/mL, had reached 34.3% ± 2.7% and 6.3% ± 1.0% of the initially applied ^14^C-label (average ± SD for three cultures). The kinetics were almost identical to those described previously for \[2-^14^C\]enrofloxacin and \[piperazine-2,3-^14^C\]enrofloxacin, respectively. Hence, the data are not shown in detail, but see Figure 2 in [@B20].

![**HPLC elution profiles of concentrated supernatants from cultures of *G. striatum*metabolizing \[2-^14^C\]PRA after 16 (A) and 42 days (B) of incubation**. In trace (B), the sensitivity of detection was increased threefold.](2191-0855-2-3-1){#F1}

Chemically synthesized reference standards could be employed to identify F-1, F-6 and F-9 by co-chromatography (Figure [2](#F2){ref-type="fig"}). F-1 and F-6 were identical with congeners of PRA, mono-hydroxylated at C-3 or C-8, respectively. Hydroxyl radical-driven elimination of the CN group, providing metabolite F-6, is notable. F-9 indicated complete degradation of the amine moiety with the C-7 amino group remaining attached to the FQ core part (Figure [3](#F3){ref-type="fig"}). Following isolation of F-1, F-6 and F-9 by micro-preparative HPLC, their structures were confirmed by HR-MS-derived molecular formulae and ^1^H-NMR analysis as well (not shown). Molecular weights, retention times and characteristics of the absorption spectra of all metabolites are compiled in Table [1](#T1){ref-type="table"}.

![**Co-chromatographic identification of PRA metabolites**. Elution profiles of chemically synthesized references are shown in traces (A): 8-OH-PRA, F-6; (B): the 7-amino metabolite of PRA, F-9; and (C): the 3-hydroxy-congener of PRA, F-1. Trace (E) represents the elution profile of concentrated supernatants. In trace (D), concentrated supernatant had been spiked by adding compounds A, B and C to approximately double their concentrations. Note the reversed order of F-6 and F-9 (as compared to Figure 1), due to the shallower gradient applied; retention times are summarized in Table 1. Absorbance was recorded at 270 nm.](2191-0855-2-3-2){#F2}

HPLC analysis of 16-day-old supernatant revealed the pattern of PRA metabolites produced (Figure [1](#F1){ref-type="fig"}). Based on previous findings, six major metabolites were designated F-1, F-2, F-5, F-6, F-9 and F-13; F denotes a type of fungal metabolite with proven chemical structure. Their concentrations amounted to 9% (F-2), 2 to 3% (F-1, F-5), and about 1% (F-6, F-9, F-13) of the ^14^C-label applied. Upon prolonged incubation (e.g., after 42 days), the concentrations of F-1, F-2, F-6 and F-5 (three mono and one dihydroxylated congeners, respectively; see below) declined extensively, while those of F-9 and F-13 remained essentially constant. At that point, even PRA had reached the concentration level typical of major metabolites. Hence, supernatants of four parallel cultures were harvested on day 16. The ^14^C-label recovered in the combined supernatants amounted to 92% of the activity applied.

![**Metabolic scheme for PRA in *G. striatum***. Degradation routes were initiated by oxidative decarboxylation (A), defluorination (B), hydroxylation of position C-8 (C), and decomposition of the amine moiety (D) which, alternatively, could be eliminated intact as F-10. Hypothetical intermediates are marked in grey: twofold oxidation of the pyrogallol-type intermediate is likely to provide a *cis,cis*-muconic acid-type metabolite, from which F-13 may be formed after two spontaneous decarboxylations.](2191-0855-2-3-3){#F3}

###### 

HPLC retention times, pseudomolecular ions in HPLC-MS, and characteristics of the UV absorption spectra of \[^14^C\]PRA and its metabolites

  ---------------------------------------------------------------------------------------
  Characteristic                         Values for                                
  ------------------------ ------ ------ ------------ ------ ------ ------ ------- ------
  Retention time (min)                                                             

  Method A                 23.8   20.2   23.3         25.3   28.1   28.6   \~2.4   15.2

  Method B                 32.0   24.7   31.4         35.2   41.0   38.7   \~2.4   16.8

  Pseudomolecular ion                                                              

  \[M+H\]^+^(*m/z*)*^a^*   397    369    395          411    388    288    127     247

  UV absorption (nm)                                                               

   λ~max~(major)           288    250    288          298    242    272    \-      280

   λ~max~(minor)           364\   278\   376\         260\   298\   328\   \-      320\
                           248    362\   392          374    330    350            362
                                  374                                              

   Shoulder                374\          260                                       
                           340                                                     
  ---------------------------------------------------------------------------------------

*a*\[M+H\]^+^was accompanied by \[M+2+H\]^+^, resulting from the ^14^C-label;

*b*Data obtained in an experiment with \[pyrrolidinopiperidine-7-^14^C\]PRA

Due to their instability, no reference compounds were available of F-2 and F-5. However, the NMR spectrum of F-2 showed two singlets (Table [2](#T2){ref-type="table"}): one, assigned to the proton at position C-5 (δ = 7.64 ppm), proved the absence of fluorine, while the other was due to the proton at C-2. The molecular weight, reduced by two atomic mass units (Table [1](#T1){ref-type="table"}), was consistent with a replacement of fluorine by a hydroxyl group. For F-5, only one singlet was observed in the aromatic region of the NMR spectrum (Table [2](#T2){ref-type="table"}): this was to be assigned to the proton at C-2. An increase in the molecular weight of 14 (Table [1](#T1){ref-type="table"}), implying the replacement of fluorine by a hydroxyl group and the addition of one oxygen atom at position C-5, implicated the catechol-type congener F-5 (Figure [3](#F3){ref-type="fig"}). The identity of F-2 and F-5 was confirmed on the basis of their molecular formulae determined by HR-MS (data not shown).

###### 

^1^H-NMR characteristics of the aromatic protons of PRA and metabolites produced by *G. striatum*

                 Chemical   Coupling
  ------ ------- ---------- ----------
  PRA    H-2     8.92       
         H-5     7.87       14.5
  F-1    H-2     8.41       
         H-5     7.96       14.8
  F-2    H-2     9.06       
         H-5     7.64       
  F-5    H-2     8.81       
  F-13   H-2     8.80       
         H-5     7.08       
         H-2\'   8.81       

Identification of metabolite F-13, 6-\[(*E/Z*)-1-cyano-2-hydroxyethenyl\]-1-cyclopropyl-4-oxo-1,4-dihydro-3-pyridinecarboxylic acid (Figure [3](#F3){ref-type="fig"}), was based on (i) its exact mass, \[M+H\]^+^= 247.0719, equating to the molecular formula C~12~H~10~N~2~O~4~; (ii) three singlets in the aromatic region of the NMR spectrum, assigned to H-5, H-2 and H-2\' (Table [2](#T2){ref-type="table"}); (iii) NMR signals of all protons of the cyclopropyl moiety (data not shown); and (iv) specific peaks of absorbance of the CN group at 2189 and 2218 cm^-1^in the FT-IR spectrum. However, whether the hydroxyl group at C-2\' was located in *cis*or *trans*position to the CN group remains to be elucidated.

The application of \[pyrrolidinopiperdine-7-^14^C\]PRA as substrate to be degraded facilitated the identification of a seventh major metabolite, F-10, the intact pyrrolidinopiperidine substituent. Its characterization proceeded exactly as has been described for the piperazine residue of enrofloxacin; see Figure 4C in [@B20]. F-10 was identified by co-chromatography, employing a chemically synthesized standard (not depicted), and confirmed by determination of its molecular weight (Table [1](#T1){ref-type="table"}).

It should be mentioned that the quantities of six additional metabolites of PRA were too small to permit comprehensive structure elucidation. Retention times and HR-MS analysis-based molecular formulae suggested the presence of (i) one additional congener each of PRA and F-1, most likely carrying a mono and a dihydroxylated amine substituent; (ii) F-2, to which one oxygen atom had been added but water eliminated; and (iii) F-9, in which fluorine was replaced by a hydroxyl group; a labile *ortho*-aminophenol-type metabolite resembling key metabolite 77 of enrofloxacin (see Figure 5 in [@B10]).

Discussion
==========

The basic metabolic pathway of PRA, a new veterinary FQ antibacterial drug, in the brown rot fungus *G. striatum*was similar to schemes established for other FQs such as enrofloxacin, ciprofloxacin and moxifloxacin. Hydroxylated primary metabolites of PRA, each representing a different class of compounds (Figure [3](#F3){ref-type="fig"}), were generated by hydroxyl radical-based decarboxylation (F-1), defluorination (F-2) and elimination of CN (F-6). The definitive identification of a catechol-type FQ congener, compound F-5, carrying one hydroxyl group each at C-5 and C-6, is described here for the first time. This was facilitated by the CN substituent blocking C-8, in contrast to F-5 of enrofloxacin [@B20] or ciprofloxacin [@B21], for which hydroxylation of position C-5 was indistinguishable from hydroxylation of C-8. Degradation of the amine substituent is represented by F-9.

The identification of metabolite F-13, consisting of the cyclopropyl-substituted pyridone part and C-atoms 7 and 8 of PRA, now linked by a double bond and carrying a hydroxyl and the CN group, respectively, proved fungal cleavage of the aromatic FQ core for the first time. The presence of a conjugated CN group was verified by IR-spectroscopy. Being part of a mesomeric system, the CN group is likely to have stabilized metabolite F-13 sufficiently as to permit its isolation and structure elucidation. The most likely intermediates, connecting F-5 with F-13 (Figure [3](#F3){ref-type="fig"}), imply: (i) hydroxyl radical-based elimination of the intact amine moiety (F-10), a reaction already observed for enrofloxacin and ciprofloxacin [@B20]; [@B21]; (ii) twofold oxidation of the resulting pyrogallol-type intermediate and the formation of a *cis,cis*-muconic acid-type analog; and (iii) spontaneous twofold decarboxylation, finally providing F-13. Metabolite F-13 adds a unique type of compound to the plethora of 137 known metabolites of enrofloxacin (including the ethylpiperazine residue and CO~2~) produced by basidiomycetous fungi [@B10];[@B23].

Six major metabolites of enrofloxacin and, in particular, 8-OH-PRA (F-6) have been shown to essentially have lost antibacterial activity [@B24];[@B25]. Most recent observations suggest that minimum inhibitory concentrations of 8-OH-PRA may have been slightly (less than twofold) overestimated, due to its instability at 37°C, resulting in a half-life of about 2 days (Wetzstein H-G, unpublished data). Regardless, FQ residues such as those described herein appear to be unlikely to pose a significant risk due to selection of resistance in agricultural soils [@B24];[@B3].

Recently, metabolites of norfloxacin hydroxylated at position C-6 and C-8 have been reported to be formed by *Microbacterium*spp. isolated from wastewater [@B11]. Moreover, from 8-OH-norfloxacin, C-8 may be eliminated by *Candida palmioleophila*LA-1 [@B11]. The corresponding metabolite should be indicative of a mechanism of aromatic ring cleavage different from that believed to be observed in this study.

Metabolic inactivation of FQs in mammals predominantly comprises glucuronidation of the carboxyl group and sulfation of an appropriate secondary amine function, if present in the amine substituent. Furthermore, *N*-4\'-dealkylation, formylation and oxide formation as well as partial degradation of the C-7 amine substituent have been observed. However, core-hydroxylated metabolites were not reported, as reviewed by [@B4]. Another major mechanism of FQ inactivation is *N-*4\'-acetylation, in case of enrofloxacin following *N*-4\'-deethylation, as catalyzed by the Zygomycete *Mucor ramannianus*[@B14]. For *G. striatum*, only *O*-acetylated congeners have been observed, exemplified by metabolites 13 and 62 described by [@B10]. Chemically synthesized *N*-acetyl-PRA provides for MICs similar to those of 8-OH-PRA (Wetzstein H-G, unpublished observation). However, it is unknown, whether PRA could serve as a substrate for the bacterial enzymes yet described.

Most notable, acetylation of the piperazine residue of ciprofloxacin or norfloxacin by environmental strains of *Mycobacterium*[@B1][@B2] has not yet been found in clinical strains. Furthermore, a FQ-resistant strain of *E. coli*, isolated from sewage sludge, contained the aminoglycoside transacetylase gene *aac(6\')-Ib-cr*and was capable of modifying ciprofloxacin by acetylation [@B9]. This activity was first observed to be a plasmid-encoded FQ-resistance factor in Gram-negative species [@B19]. *N*-acetylation as well as N-oxide formation [@B14];[@B10] eliminates the positive charge of the amine residue, present at physiological pH. The resulting FQ congener is negatively charged, thus drug accumulation into the cytoplasm may be restricted or even prevented.

Strangely enough, the apparently complex degradation scheme described for enrofloxacin [@B10];[@B23] has to be considered a relatively simple example, compared to degradation patterns to be expected for PRA, moxifloxacin and any other FQ with a more complex amine substituent. Giving rise to the variety of constitutional isomers, the number of discernible H-atoms in the amine moiety, potentially to be replaced by a hydroxyl group, amounts to four for enrofloxacin, but already to twelve for the pyrrolidinopiperidine residue of PRA; this structural feature extends to metabolites carrying a combination of a hydroxyl and a keto group or even a cleaved amine moiety. Hence, definitive structure elucidation of such metabolites would have to be based on isolated compounds and required a formidable analytical effort.

In independent studies assessing the chemical degradation of enrofloxacin, ciprofloxacin or other FQs, cleavage of the aromatic core could not yet be proved either, if based on metabolite identification. Work on ciprofloxacin confirmed several key metabolites observed with *G. striatum*: (i) F-1, F-2, F-6 and F-9 in a membrane anodic Fenton-type system ([@B26]; see also references 19, 22 and 25, therein); (ii) isatin and anthranilic acid-type metabolites formed during ozonation ([@B5]; and (iii) metabolites indicating degradation of the amine substituent by hydroxyl radicals, generated upon UV-irradiation of TiO~2~[@B15]. Under the latter conditions, cleavage of the cyclopropyl moiety was observed as well. This leaves unexplored fungal degradation of the cyclopropyl-substituent, which, however, is a natural product found, e.g., in the lipids of *E. coli*[@B7]. Two decades after the emergence of the notion of the non-biodegradability of FQs, briefly reviewed by [@B24], fungal degradation of all key structural elements of a FQ, in particular of the aromatic core, now has been proven.
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